全文获取类型
收费全文 | 33623篇 |
免费 | 2105篇 |
国内免费 | 3336篇 |
专业分类
林业 | 1810篇 |
农学 | 2707篇 |
基础科学 | 919篇 |
10295篇 | |
综合类 | 11912篇 |
农作物 | 3089篇 |
水产渔业 | 1137篇 |
畜牧兽医 | 4509篇 |
园艺 | 1522篇 |
植物保护 | 1164篇 |
出版年
2024年 | 235篇 |
2023年 | 803篇 |
2022年 | 1363篇 |
2021年 | 1526篇 |
2020年 | 1508篇 |
2019年 | 1789篇 |
2018年 | 1558篇 |
2017年 | 1813篇 |
2016年 | 2237篇 |
2015年 | 2043篇 |
2014年 | 2158篇 |
2013年 | 3000篇 |
2012年 | 3149篇 |
2011年 | 2151篇 |
2010年 | 1705篇 |
2009年 | 1639篇 |
2008年 | 1298篇 |
2007年 | 1501篇 |
2006年 | 1415篇 |
2005年 | 1171篇 |
2004年 | 766篇 |
2003年 | 586篇 |
2002年 | 493篇 |
2001年 | 416篇 |
2000年 | 385篇 |
1999年 | 314篇 |
1998年 | 282篇 |
1997年 | 228篇 |
1996年 | 200篇 |
1995年 | 231篇 |
1994年 | 165篇 |
1993年 | 167篇 |
1992年 | 124篇 |
1991年 | 118篇 |
1990年 | 105篇 |
1989年 | 108篇 |
1988年 | 69篇 |
1987年 | 46篇 |
1986年 | 35篇 |
1985年 | 39篇 |
1984年 | 26篇 |
1983年 | 16篇 |
1982年 | 8篇 |
1981年 | 23篇 |
1980年 | 14篇 |
1979年 | 7篇 |
1978年 | 9篇 |
1977年 | 5篇 |
1975年 | 3篇 |
1962年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
941.
942.
H. Yamazaki S. Takagi N. Oh Y. Hoshino K. Hosoya M. Okumura 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2014,28(1):204-210
Background
Definitive diagnosis of histiocytic sarcoma (HS) in dogs is relatively difficult by conventional histopathological examination because objective features of HS are not well defined.Hypothesis
Quantitative analysis of mRNA expression of selected cellular surface antigens (SAs) specific to HS in dogs can facilitate objective and rapid diagnosis.Animals
Dogs with HS (n = 30) and dogs without HS (n = 36), including those with other forms of lymphoma (n = 4), inflammatory diseases (n = 6), and other malignant neoplasias (n = 26).Methods
Retrospective clinical observational study. Specimens were collected by excisional biopsy, needle core biopsy, or fine needle aspiration. To determine HS detection efficacy, mRNA expression levels of selected SAs specific to HS in dogs, including MHC class IIα, CD11b, CD11c, and CD86, were quantitatively analyzed using real‐time quantitative polymerase chain reaction.Results
Each SA mRNA expression level was significantly higher in HS dogs than in non‐HS dogs (P = .0082). Cutoff values for discriminating between HS and non‐HS dogs based on these expression levels were calculated on the basis of receiver‐operating characteristic analysis. Accuracy of the cutoff values, including MHC class IIα, CD11b, CD11c, and CD86, was 87.9, 86.4, 86.4, and 84.8%, respectively.Conclusions and Clinical Importance
Our results suggest that quantitative analysis of mRNA expression of the selected SAs could be an adjunctive diagnostic technique with high diagnostic accuracy for HS in dogs. Substantial investigation is required for exclusion of diseases with similar cell types of origin to lymphoma. 相似文献943.
944.
Detection of Clinically Relevant Pain Relief in Cats with Degenerative Joint Disease Associated Pain
M.E. Gruen E. Griffith A. Thomson W. Simpson B.D.X. Lascelles 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2014,28(2):346-350
Background
Detection of clinically relevant pain relief in cats with degenerative joint disease (DJD) is complicated by a lack of validated outcome measures and a placebo effect.Hypothesis/Objectives
To evaluate a novel approach for detection of pain relief in cats with DJD.Animals
Fifty‐eight client‐owned cats.Methods
Prospective, double‐masked, placebo‐controlled, stratified, randomized, clinical study. Enrolled cats were 6–21 years of age, with owner‐observed mobility impairment, evidence of pain in at least 2 joints during orthopedic examination, and overlapping radiographic evidence of DJD, and underwent a 2‐week baseline period, 3‐week treatment period with placebo or meloxicam, and 3‐week masked washout period. Outcome measures were evaluated at days 0, 15, 36, and 57.Results
Both groups significantly improved after the treatment period (day 36) on client‐specific outcome measures (CSOM) and feline musculoskeletal pain index (FMPI) (P < .0001 for both); there was no difference between the groups on CSOM or FMPI score improvement. After the masked washout period, more cats that received meloxicam during the treatment period had a clinically relevant decrease in CSOM score (P = .048) and FMPI score (P = .021) than cats that received placebo.Conclusions and Clinical Importance
Using both a client‐specific and a general clinical metrology instrument, owners of cats with DJD were able to detect evident recurrence of clinical signs after withdrawal of active medication than after withdrawal of placebo, and that this study design might be a novel and useful way to circumvent the placebo effect and detect the efficacy of pain‐relieving medications. 相似文献945.
K. Sjstrand G. Wess I. Ljungvall J. Hggstrm A‐C. Merveille M. Wiberg V. Gouni J. Lundgren Willesen S. Hans A‐S. Lequarr L. Mejer Srensen J. Wolf L. Tiret M. Kierczak S. Forsberg K. McEntee G. Battaille E. Seppl K. Lindblad‐Toh M. Georges Hannes Lohi V. Chetboul M. Fredholm K. Hglund 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2014,28(2):451-457
Background
Measurement of plasma concentration of natriuretic peptides (NPs) is suggested to be of value in diagnosis of cardiac disease in dogs, but many factors other than cardiac status may influence their concentrations. Dog breed potentially is 1 such factor.Objective
To investigate breed variation in plasma concentrations of pro‐atrial natriuretic peptide 31‐67 (proANP 31‐67) and N‐terminal B‐type natriuretic peptide (NT‐proBNP) in healthy dogs.Animals
535 healthy, privately owned dogs of 9 breeds were examined at 5 centers as part of the European Union (EU) LUPA project.Methods
Absence of cardiovascular disease or other clinically relevant organ‐related or systemic disease was ensured by thorough clinical investigation. Plasma concentrations of proANP 31‐67 and NT‐proBNP were measured by commercially available ELISA assays.Results
Overall significant breed differences were found in proANP 31‐67 (P < .0001) and NT‐proBNP (P < .0001) concentrations. Pair‐wise comparisons between breeds differed in approximately 50% of comparisons for proANP 31‐67 as well as NT‐proBNP concentrations, both when including all centers and within each center. Interquartile range was large for many breeds, especially for NT‐proBNP. Among included breeds, Labrador Retrievers and Newfoundlands had highest median NT‐proBNP concentrations with concentrations 3 times as high as those of Dachshunds. German Shepherds and Cavalier King Charles Spaniels had the highest median proANP 31‐67 concentrations, twice the median concentration in Doberman Pinschers.Conclusions and Clinical Importance
Considerable interbreed variation in plasma NP concentrations was found in healthy dogs. Intrabreed variation was large in several breeds, especially for NT‐proBNP. Additional studies are needed to establish breed‐specific reference ranges. 相似文献946.
J.D. Foster S. Sample R. Kohler K. Watson P. Muir L.A. Trepanier 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2014,28(3):905-911
Background
Immune‐mediated polyarthopathy (IMPA) is common in dogs, and is monitored by serial arthrocenteses.Hypothesis/Objectives
Plasma C‐reactive protein (CRP), interleukin‐6 (IL‐6), and CXCL8 (interleukin‐8) would serve as noninvasive markers of joint inflammation in IMPA.Animals
Nine client‐owned dogs with idiopathic IMPA; 6 healthy controls.Methods
Prospective study. Plasma CRP, IL‐6, and CXCL8 were measured by ELISA at baseline, 2, and 4 weeks during treatment with prednisone at 50 mg/m2/day. Arthrocenteses, the canine brief pain inventory (CBPI), and accelerometry collars were used to assess joint inflammation, lameness, and mobility at all 3 time points.Results
C‐reactive protein concentrations were higher in IMPA dogs (median 91.1 μg/mL, range 76.7–195.0) compared with controls (median <6.3 μg/mL, <6.3–13.7; P = .0035), and were significantly lower at week 2 (10.6 μg/mL, <6.3–48.8) and week 4 (<6.3 μg/mL, <6.3–24.4; P < .001).C‐reactive protein was correlated with median CBPI scores (r = 0.68; P = .0004), joint cellularity (r = 0.49, P = .011), and mobility by accelerometry (r = −0.42, P = .048). Plasma IL‐6 concentrations were also higher in IMPA dogs (median 45.9 pg/mL), compared with controls (median <15.7 pg/mL; P = .0008). IL‐6 was lower in IMPA dogs by week 4 (<15.7 pg/mL; P = .0099), and was modestly correlated with CBPI scores (r = 0.47, P = .023). CXCL8 did not differ significantly between IMPA and healthy dogs.Conclusions
Plasma CRP and IL‐6 might be useful surrogate markers of synovial inflammation and disease activity in dogs with IMPA. 相似文献947.
Noboru KUDO Chieko OTA Fumiko SAKA Yae IKEDA Yusuke TOMIHISA Yasunaga ITOI Takashi OYAMADA 《The Journal of veterinary medical science / the Japanese Society of Veterinary Science》2014,76(12):1651-1654
Seven laboratory mammal and
bird species were orally inoculated with 200–1,000 encysted Metagonimus
hakubaensis metacercariae that had been isolated from naturally infected
lampreys (Lethenteron reissneri) captured in Aomori Prefecture. At 8 and
15 days post-infection, adult flukes were recovered from all of the laboratory animals
tested, and therefore, hamster, rat, mouse, dog, cat, chicken and quail were considered as
final hosts of M. hakubaensis. Recovery rates of the fluke were higher in
dogs and hamsters than in cats, rats, mice, chickens and quails. The flukes recovered from
dogs and hamsters showed increased body length and higher fecundity than those recovered
from the other hosts. These results indicate that the suitability of dogs and hamsters for
M. hakubaensis infection is higher than that of the other laboratory
animals. 相似文献
948.
949.
Jane C.F. Chang Paul Ciaccio Patricia Schroeder Lindsay Wright Russell Westwood Anna-Lena Berg 《Journal of toxicologic pathology》2014,27(1):31-42
AZD3783, a cationic amphiphilic drug and a potent inhibitor of the 5-hydroxytryptamine
(5-HT1B) receptor, was explored as a potential treatment for depression. To
support clinical trials, repeat dose toxicity studies in rats and dogs were conducted.
Here we report toxicity findings in dogs after dosing from 1 to 3 months. In the 1-month
study, there were minimal neuronal vacuolation in the brain, a marked increase in liver
enzymes accompanied by hepatocellular degeneration/necrosis and phospholipidosis (PLD),
and PLD/cholecystitis in the gallbladder of animals dosed at 47 mg/kg/day. In the 3-month
study, neurotoxicity resulted in euthanasia of one animal dosed at 30 mg/kg/day after 86
days. Extensive pathologic changes were seen in all animals in retina epithelium
(inclusion bodies), brain (neuronal vacuolation, degeneration, or necrosis and nerve fiber
degeneration), spinal ganglia (vacuolation, degeneration, or necrosis), as well as sciatic
and optic nerves (degeneration). Pigment-laden macrophages were observed in the lung,
kidney, liver, gallbladder, bone marrow, gastrointestinal tract, and lymphoid tissues.
Also seen were vitrel and retinal hemorrhage in the eyes. A brain concentration and
pathology study showed that the concentration of AZD3783 in the brain was approximately 4
times higher than in the plasma after 4 weeks of dosing, however, they were similar in all
regions examined, and did not correlate with areas with pathologic findings. Our findings
with AZD3783 in dogs have not been reported previously with other CNS compounds that
effect through serotonergic pharmacology. 相似文献
950.
K. Nakamura T. Osuga K. Morishita S. Suzuki T. Morita N. Yokoyama H. Ohta M. Yamasaki M. Takiguchi 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2014,28(6):1746-1752